Cited 0 times in
Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma A STROBE study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, JP | - |
dc.contributor.author | Moon, JH | - |
dc.contributor.author | Kim, HK | - |
dc.contributor.author | Lee, MH | - |
dc.contributor.author | Lim, CH | - |
dc.contributor.author | Park, SB | - |
dc.contributor.author | Yoon, JK | - |
dc.contributor.author | Park, JM | - |
dc.date.accessioned | 2023-01-05T03:03:50Z | - |
dc.date.available | 2023-01-05T03:03:50Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/23791 | - |
dc.description.abstract | The purpose of this study was to determine the glucose metabolism at delay phase measured by pretreatment dual-time-point 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/ computed tomography (CT) provides prognostic information independent of well-known prognostic factors in patients with intrahepatic or perihilar cholangiocarcinoma (ICC or PCC). From July 2012 to December 2017, 55 patients (men 27, women 28, mean age 68 ± 11 years) with pathologically proven ICC or PCC were enrolled in this retrospective study. The dual-time-point 18F-FDG PET/CT as part of a staging workup was performed in all patients. The patient’s data includes age, sex, serum CA19-9, presence of LN or distant metastasis, early SUVmax (early maximum standardized uptake value [eSUV]), delay SUVmax (delay maximum standardized uptake value [dSUV]), retention index of SUVmax (percent change of maximum standardized uptake values [DSUV]), neutrophil to lymphocyte ratio (NLR) and histopathology including pCEA, p53, Ki-67 index. The analysis of the relationship between metabolic parameters and survival was done using the Kaplan–Meier curve and Cox proportional hazards regression model. Median survival for all patients was 357 days. Median early and delay SUVmax was 5.2 (range: 2.0–21.4) and 6.5 (range 2.7–24.5), respectively. The overall survival was found to be significantly related to eSUV, dSUV, DSUV, age, serum CA19-9 and NLR in univariate analysis. In multivariate analysis, dSUV (P = .014, 95%CI; 1.30–10.7, HR 3.74) and DSUVmax (P = .037, 95%CI; 1.05–6.12, HR 2.5) were independent factors of overall survival. Kaplan–Meier curve analysis clearly showed the significant difference of overall survival between 2 groups (high eSUV, low eSUV + high DSUV vs low eSUV and DSUV, P < .001) among the comparisons of the SUV parameters on FDG PET. In the receiver operating characteristic analysis using combinations of the SUV parameters, the 2 groups [eSUV + DSUV (P = .0001, area under the curve [AUC] 0.68) and dSUV + DSUV (P = .0002, AUC 0.71)] showed significantly larger AUC than the other groups applying eSUV or dSUV alone (AUC 0.61 and AUC 0.68). dSUV and DSUV on pretreatment dual-time-point 18F-FDG PET/CT can be useful parameters in the prediction of survival in patients with ICC or PCC. | - |
dc.language.iso | en | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Bile Duct Neoplasms | - |
dc.subject.MESH | Bile Ducts, Intrahepatic | - |
dc.subject.MESH | Feasibility Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18 | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Klatskin Tumor | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Radiopharmaceuticals | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | ROC Curve | - |
dc.title | Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma A STROBE study | - |
dc.type | Article | - |
dc.identifier.pmid | 34032720 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154415/ | - |
dc.contributor.affiliatedAuthor | Yoon, JK | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1097/MD.0000000000026015 | - |
dc.citation.title | Medicine | - |
dc.citation.volume | 100 | - |
dc.citation.number | 21 | - |
dc.citation.date | 2021 | - |
dc.citation.startPage | e26015 | - |
dc.citation.endPage | e26015 | - |
dc.identifier.bibliographicCitation | Medicine, 100(21). : e26015-e26015, 2021 | - |
dc.identifier.eissn | 1536-5964 | - |
dc.relation.journalid | J000257974 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.